利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

510 条记录 (耗时 0.023 秒)

    ANTITUMOR EFFECT FORTIFIER, ANTITUMOR AGENT AND METHOD OF THERAPY FOR CANCER
    55.
    发明公开
    ANTITUMOR EFFECT FORTIFIER, ANTITUMOR AGENT AND METHOD OF THERAPY FOR CANCER 有权
    加固肿瘤作用，抗肿瘤药物和治疗癌症过程来

    公开(公告)号：EP1757283A4

    公开(公告)日：2009-09-02

    申请号：EP05745983

    申请日：2005-06-02

    申请人： TAIHO PHARMACEUTICAL CO LTD

    发明人： KOIZUMI KATSUHISA ,  UCHIDA JUNJI ,  TAKECHI TEIJI ,  NUKATSUKA MAMORU

    IPC分类号： A61K31/132 ,  A61K31/44 ,  A61K31/506 ,  A61K31/53 ,  A61K33/24 ,  A61K45/06 ,  A61P35/00

    CPC分类号： A61K45/06 ,  A61K31/132 ,  A61K31/44 ,  A61K31/506 ,  A61K31/53 ,  A61K33/24 ,  A61K2300/00

    摘要： An antitumor effect fortifier comprising as an active ingredient an effective amount of platinum (II) cis-oxalato(1R,2R-diaminocyclohexane) so as to enhance the antitumor activity of antitumor agent containing a therapeutically effective amount of tegafur, an amount, effective for the enhancement of antitumor effect, of gimeracil and an amount, effective for the suppression of side effects, of oteracil potassium; and a relevant antitumor agent. Further, there is provided a method of therapy for cancer, characterized in that an amount, effective for the enhancement of antitumor effect, of platinum (II) cis-oxalato(1R,2R-diaminocyclohexane) is concomitantly administered to a mammal. Still further, there is provided an antitumor agent consisting of a pharmaceutical preparation form composed of at least two separate preparations containing efficacious ingredients consisting of tegafur, gimeracil, oteracil potassium and platinum (II) cis-oxalato(1R,2R-diaminocyclohexane) each alone or in an arbitrary combination, or a pharmaceutical preparation form constituted of a single preparation containing all the efficacious ingredients. Still further, there is provided a relevant kit.

    NONBACTERIAL PROSTATITIS MODEL ANIMAL
    58.
    发明公开
    NONBACTERIAL PROSTATITIS MODEL ANIMAL 审中-公开
    不是细菌动物模型前列腺炎

    公开(公告)号：EP1559317A4

    公开(公告)日：2007-10-24

    申请号：EP03758961

    申请日：2003-10-28

    申请人： TAIHO PHARMACEUTICAL CO LTD

    发明人： NAKANO KOUSHI ,  KIRIMOTO TSUKASA ,  HAYASHI YUKIO ,  OKA TOSHINORI

    IPC分类号： A01K67/027 ,  A61K45/00 ,  A61K49/00 ,  A61P13/08 ,  G01N33/15 ,  G01N33/50

    CPC分类号： A61K49/0008 ,  A01K2267/0368

    摘要： It is intended to provide a model animal which is useful in developing a preventive or a remedy for human chronic nonbacterial prostatitis, more specifically speaking, a nonhuman model animal of nonbacterial prostatitis having pathologic conditions simulating human chronic nonbacterial prostatitis. The above nonbacterial prostatitis model animal is constructed by injecting hydrochloric acid under the prostatic membrane and characterized by having a tissue injury characteristically observed human chronic nonbacterial prostatitis in the prostatic tissue as well as a lower urinary tract injury characteristically observed in human chronic nonbacterial prostatitis.

    METHOD OF EVALUATING EVENNESS OF SUPLATAST TOSILATE CRYSTAL, EVEN CRYSTAL, AND PROCESS FOR PRODUCING THE SAME
    59.
    发明公开
    METHOD OF EVALUATING EVENNESS OF SUPLATAST TOSILATE CRYSTAL, EVEN CRYSTAL, AND PROCESS FOR PRODUCING THE SAME 有权
    一个SUPLATASTTOSILATKRISTALLS，均匀的晶体的评估处理的均匀性和方法及其

    公开(公告)号：EP1777217A1

    公开(公告)日：2007-04-25

    申请号：EP05759961.5

    申请日：2005-07-13

    申请人： TAIHO PHARMACEUTICAL CO., LTD.

    发明人： USHIO, Takanori c/o Taiho Pharmaceutical Co., Ltd. ,  NAGAI, Keiko, c/o Taiho Pharmaceutical Co., Ltd.

    IPC分类号： C07C381/12 ,  G01N21/21 ,  G01N23/20 ,  A61K31/167 ,  A61P37/08

    CPC分类号： C07C381/12 ,  A61K31/167 ,  G01N21/3563

    摘要： Provided are a method for evaluating evenness of suplatast tosilate crystals; stable suplatast tosilate crystals exhibiting evenness in optical purity; and a method for producing the suplatast tosilate crystals.
    The method for evaluating evenness of suplatast tosilate crystals includes: (a) a step of adding a solvent to suplatast tosilate crystals to thereby dissolve 3% or less of the crystals in the solvent, and subjecting a portion of the supernatant of the resultant suspension to optical purity measurement, and (b) a step of adding a solvent to the remaining suspension to thereby dissolve the entirety of the suspension in the solvent, and subjecting a portion of the resultant solution to optical purity measurement, wherein the optical purity as measured in the step (a) is compared with the optical purity as measured in the step (b). The suplatast tosilate crystals exhibits excellent evenness and thermal stability. The method for producing the suplatast tosilate crystals is also provided.

    摘要翻译： 提供的是用于评价甲磺司特结晶的均匀性的方法; STA评定甲磺司特结晶的均匀性的方法，包括：（a）一种

    PENICILLIN CRYSTAL AND PROCESS FOR PRODUCING THE SAME
    60.
    发明公开
    PENICILLIN CRYSTAL AND PROCESS FOR PRODUCING THE SAME 有权
    PENICILLINKRISTALL UND VERFAHREN ZU DESSEN HERSTELLUNG

    公开(公告)号：EP1671974A1

    公开(公告)日：2006-06-21

    申请号：EP04773756.4

    申请日：2004-10-08

    申请人： OTSUKA CHEMICAL COMPANY, LIMITED ,  TAIHO PHARMACEUTICAL CO., LTD.

    发明人： WADA, Isao, c/o OTSUKA CHEMICAL CO., LTD. ,  KAMEYAMA, Yutaka, c/o OTSUKA CHEMICAL CO., LTD.

    IPC分类号： C07D499/00

    CPC分类号： C07D499/86

    摘要： The present invention provides 2β-chloromethyl-2α-methylpenam-3α-carboxylic acid benzhydryl ester (CMPB) crystals of excellent stability, and a process for producing the CMPB crystals comprising the steps of (A) concentrating a solution containing CMPB; (b) subjecting the thus-obtained concentrate to column chromatography; (C) concentrating a CMPB-containing fraction; and (D) dissolving the thus-obtained CMPB-containing concentrate in an ether solvent and adding a hydrocarbon solvent to the resulting solution to precipitate CMPB crystals.

    摘要翻译： 本发明提供了具有优异稳定性的2β-氯甲基-2± - 甲基氨基-3'-羧酸二苯甲基酯（CMPB）晶体，以及制备CMPB晶体的方法，包括以下步骤：（A）浓缩含有CMPB的溶液; （b）将由此得到的浓缩物进行柱色谱; （C）浓缩含CMPB的级分; 和（D）将由此获得的含CMPB的浓缩物溶解在醚溶剂中并向所得溶液中加入烃溶剂以沉淀CMPB晶体。